| scholarly article | Q13442814 |
| P356 | DOI | 10.1016/S0022-5223(99)70469-1 |
| P698 | PubMed publication ID | 9869758 |
| P2093 | author name string | Strauss GM | |
| Richards WG | |||
| Corson JM | |||
| DeCamp MM Jr | |||
| Sugarbaker DJ | |||
| Mentzer SJ | |||
| Swanson SJ | |||
| Baldini EH | |||
| Lukanich JM | |||
| Bueno R | |||
| Jaklitsch MT | |||
| Flores RM | |||
| P2860 | cites work | Phase III randomized trial of surgery with or without intraoperative photodynamic therapy and postoperative immunochemotherapy for malignant pleural mesothelioma | Q32161570 |
| A proposed new international TNM staging system for malignant pleural mesothelioma. From the International Mesothelioma Interest Group | Q34295028 | ||
| Development of postoperative intrathoracic chemo-thermotherapy for lung cancer with objective of improving local cure | Q34416934 | ||
| Efficacy of cisplatin-based intraperitoneal chemotherapy as treatment of malignant peritoneal mesothelioma | Q34562049 | ||
| Pleuropneumonectomy in the management of diffuse malignant mesothelioma of the pleura. Experience with 29 patients | Q36437220 | ||
| Chemotherapy in malignant mesothelioma: a review | Q37367440 | ||
| Experimental and clinical status of intraperitoneal chemotherapy | Q37858356 | ||
| Recent trends in mesothelioma incidence in the United States | Q39790318 | ||
| Patterns of failure after trimodality therapy for malignant pleural mesothelioma | Q40906267 | ||
| Diffuse malignant mesothelioma of the pleura in Ontario and Quebec: a retrospective study of 332 patients | Q41226875 | ||
| Advanced ovarian cancer: Primary treatment with surgery, radiotherapy, and chemotherapy | Q44199146 | ||
| Analysis of morbidity and mortality in 60 patients with peritoneal carcinomatosis treated by cytoreductive surgery and heated intraoperative intraperitoneal chemotherapy. | Q51031869 | ||
| Extrapleural pneumonectomy in the treatment of malignant pleural mesothelioma | Q67568428 | ||
| Pentetration of carboplatin and cisplatin into rat peritoneal tumor nodules after intraperitoneal chemotherapy | Q67919758 | ||
| Extrapleural pneumonectomy in the setting of a multimodality approach to malignant mesothelioma | Q70633765 | ||
| Node status has prognostic significance in the multimodality therapy of diffuse, malignant mesothelioma | Q70736032 | ||
| Extrapleural pneumonectomy in the multimodality therapy of malignant pleural mesothelioma. Results in 120 consecutive patients | Q71545796 | ||
| Intrapleural photodynamic therapy: results of a phase I trial | Q72452658 | ||
| A phase II trial of pleurectomy/decortication followed by intrapleural and systemic chemotherapy for malignant pleural mesothelioma | Q72504201 | ||
| Effectiveness of cisplatin, paclitaxel, and suramin against human malignant mesothelioma xenografts in athymic nude mice | Q74257154 | ||
| P433 | issue | 1 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | patient | Q181600 |
| malignant pleural mesothelioma | Q18557602 | ||
| P304 | page(s) | 54-63; discussion 63-5 | |
| P577 | publication date | 1999-01-01 | |
| P1433 | published in | The Journal of Thoracic and Cardiovascular Surgery | Q2795598 |
| P1476 | title | Resection margins, extrapleural nodal status, and cell type determine postoperative long-term survival in trimodality therapy of malignant pleural mesothelioma: results in 183 patients | |
| P478 | volume | 117 |
| Q87936775 | 18F-FDG PET/CT in the management of patients with malignant pleural mesothelioma being considered for multimodality therapy: experience of a tertiary referral center |
| Q30474771 | A 26-year-old male with mesothelioma due to asbestos exposure |
| Q46170767 | A feasibility study of induction pemetrexed plus cisplatin followed by extrapleural pneumonectomy and postoperative hemithoracic radiation for malignant pleural mesothelioma |
| Q39434224 | A nuanced view of extrapleural pneumonectomy for malignant pleural mesothelioma |
| Q33840661 | A nuclear grading system is a strong predictor of survival in epitheloid diffuse malignant pleural mesothelioma |
| Q33378432 | A phase 2 study of gemcitabine and epirubicin for the treatment of pleural mesothelioma: a North Central Cancer Treatment Study, N0021. |
| Q59132458 | A randomized phase II study of pleurectomy/decortication preceded or followed by (neo-)adjuvant chemotherapy in patients with early stage malignant pleural mesothelioma (EORTC 1205) |
| Q51760705 | A systematic review of lung-sparing extirpative surgery for pleural mesothelioma. |
| Q41807591 | Accelerated large volume irradiation with dynamic Jaw/Dynamic Couch Helical Tomotherapy |
| Q36948470 | Accuracy of pleural biopsy using thoracoscopy for the diagnosis of histologic subtype in patients with malignant pleural mesothelioma |
| Q35142860 | Advances in the management of malignant mesothelioma |
| Q37070229 | Advances in the systemic therapy of malignant pleural mesothelioma |
| Q38800916 | Advances in treatment of mesothelioma. |
| Q51757551 | Analysis of the effect of radiotherapy on malignant pleural mesothelioma when given on adjuvant or palliative basis |
| Q36643416 | Angiogenesis is an independent prognostic factor in malignant mesothelioma |
| Q38004067 | Anti-angiogenic therapies for malignant pleural mesothelioma |
| Q54779306 | Association Between Clinicopathological Factors and Genomic Abnormalities Detected by FISH Analysis in Epithelioid Diffuse Malignant Pleural Mesothelioma. |
| Q34205927 | Automated ancillary cancer history classification for mesothelioma patients from free-text clinical reports |
| Q30478994 | BTS statement on malignant mesothelioma in the UK, 2007. |
| Q39400036 | BioKnife, a uPA activity-dependent oncolytic Sendai virus, eliminates pleural spread of malignant mesothelioma via simultaneous stimulation of uPA expression |
| Q54516140 | Cadherins, catenins and APC in pleural malignant mesothelioma |
| Q38083599 | Changes in lung function after surgery for mesothelioma |
| Q46971325 | Changes in pulmonary function tests predict radiological response to chemotherapy in malignant pleural mesothelioma. |
| Q51206145 | Changes of mesothelin and osteopontin levels over time in formerly asbestos-exposed power industry workers. |
| Q44244488 | Characteristics of Malignant Pleural Mesothelioma in Women |
| Q43416265 | Chronic inflammation in tumor stroma is an independent predictor of prolonged survival in epithelioid malignant pleural mesothelioma patients. |
| Q53251663 | Circulating and tumor-infiltrating myeloid cells predict survival in human pleural mesothelioma. |
| Q50050310 | Clinical and biologic prognostic factors in malignant pleural mesothelioma |
| Q35234034 | Clinical experience of volumetric modulated arc therapy for malignant pleural mesothelioma after extrapleural pneumonectomy |
| Q40301690 | Clinical impact of extrapleural pneumonectomy for malignant pleural mesothelioma |
| Q51578818 | Clinical investigation of malignant mesothelioma in Japan. |
| Q36345736 | Clinical role of a new prognostic score using platelet-to-lymphocyte ratio in patients with malignant pleural mesothelioma undergoing extrapleural pneumonectomy |
| Q47836088 | Clinicopathologic and genetic characteristics of young patients with pleural diffuse malignant mesothelioma |
| Q41920935 | Combined serum mesothelin and carcinoembryonic antigen measurement in the diagnosis of malignant mesothelioma |
| Q40688498 | Comorbidity, postoperative morbidity and survival in patients undergoing radical surgery for malignant pleural mesothelioma. |
| Q37368672 | Comparison of CT and integrated PET-CT based radiation therapy planning in patients with malignant pleural mesothelioma |
| Q37086026 | Current concepts in malignant pleural mesothelioma. |
| Q37817035 | Current evidence base of FDG-PET/CT imaging in the clinical management of malignant pleural mesothelioma: emerging significance of image segmentation and global disease assessment |
| Q74226579 | Current surgical management of malignant pleural mesothelioma |
| Q38641574 | Current surgical strategies for malignant pleural mesothelioma |
| Q37232309 | Current therapies for malignant pleural mesothelioma |
| Q34666382 | Current therapy for malignant mesothelioma |
| Q39041991 | Cytoreductive surgery and hyperthermic intrapleural chemotherapy for malignant pleural diseases: preliminary experience |
| Q57781438 | Deciduoid mesothelioma of the thorax: A comprehensive review of the scientific literature |
| Q81042649 | Diagnosis of a malignant mesothelioma by EUS-guided FNA of a mediastinal lymph node |
| Q30371725 | Diagnosis, staging, and surgical treatment of malignant pleural mesothelioma. |
| Q92473856 | Diagnostic value of biopsy sampling in predicting histology in patients with diffuse malignant pleural mesothelioma |
| Q34248396 | Diaphragmatic Herniation through Prosthetic Material after Extrapleural Pneumonectomy: Be Aware of Tumor Recurrence |
| Q79717980 | Diffuse malignant pleural mesothelioma: a multi-institutional clinicopathological study |
| Q26849620 | Discovery of new biomarkers for malignant mesothelioma |
| Q92594172 | Dosimetric Comparison of Lung-Sparing Radiation Therapy between Volumetric Arc Therapy and Helical Tomotherapy for Unresectable Malignant Pleural Mesothelioma |
| Q36493568 | ENOX2-based early detection (ONCOblot) of asbestos-induced malignant mesothelioma 4-10 years in advance of clinical symptoms |
| Q93106182 | EPHA2 mutations with oncogenic characteristics in squamous cell lung cancer and malignant pleural mesothelioma |
| Q83206656 | Early mesothelioma revisited |
| Q58765920 | Early-stage Clinical Characterization of Malignant Pleural Mesothelioma |
| Q84780390 | Effects of hyaluronic acid and CD44 interaction on the proliferation and invasiveness of malignant pleural mesothelioma |
| Q64248928 | Endobronchial ultrasound-guided transbronchial needle aspiration mediastinal lymph node staging in malignant pleural mesothelioma |
| Q80159047 | Endoscopic ultrasound-guided fine needle aspiration is useful for nodal staging in patients with pleural mesothelioma |
| Q35960203 | External beam radiation therapy for the treatment of pleural mesothelioma |
| Q64080942 | Extra-pleural pneumonectomy |
| Q39860472 | Extra-pleural pneumonectomy in the setting of tri-modality therapy for patients with malignant pleural mesothelioma |
| Q35141809 | Extra-pleural pneumonectomy versus no extra-pleural pneumonectomy for patients with malignant pleural mesothelioma: clinical outcomes of the Mesothelioma and Radical Surgery (MARS) randomised feasibility study |
| Q33871592 | Extrapleural pneumonectomy (EPP) vs. pleurectomy decortication (P/D). |
| Q42552072 | Extrapleural pneumonectomy and extended pleurectomy/decortication for malignant pleural mesothelioma: the Memorial Sloan-Kettering Cancer Center approach |
| Q73638701 | Extrapleural pneumonectomy for diffuse malignant pleural mesothelioma. A treatment option in selected cases? |
| Q35782796 | Extrapleural pneumonectomy in the treatment of epithelioid malignant pleural mesothelioma: novel prognostic implications of combined N1 and N2 nodal involvement based on experience in 529 patients |
| Q59137555 | Extrapleural pneumonectomy: still indicated? |
| Q44610633 | Factors influencing long-term survival in mesothelioma patients--results of the German mesothelioma register |
| Q28389535 | Factors that impact susceptibility to fiber-induced health effects |
| Q47860659 | Flex-rigid pleuroscopy under local anesthesia in patients with dry pleural dissemination on radiography |
| Q37180702 | Four-gene expression ratio test for survival in patients undergoing surgery for mesothelioma |
| Q37449036 | Future developments in the management of malignant pleural mesothelioma |
| Q54698040 | Gemcitabine and vinorelbine as second-line or beyond treatment in patients with malignant pleural mesothelioma pretreated with platinum plus pemetrexed chemotherapy. |
| Q33348171 | Gemcitabine combined with carboplatin in patients with malignant pleural mesothelioma: a multicentric phase II study |
| Q33503255 | Global gene expression profiling of human pleural mesotheliomas: identification of matrix metalloproteinase 14 (MMP-14) as potential tumour target |
| Q28394028 | Guidelines for the diagnosis and treatment of malignant pleural mesothelioma |
| Q44850508 | Guidelines on asbestos-related pleuropulmonary disease |
| Q47746173 | Hemithoracic radiation after extrapleural pneumonectomy for malignant pleural mesothelioma |
| Q55481165 | Heterogeneity in Immune Cell Content in Malignant Pleural Mesothelioma. |
| Q43802258 | Histone deacetylase inhibitor downregulation of bcl-xl gene expression leads to apoptotic cell death in mesothelioma |
| Q37662700 | Histone deacetylase inhibitors in malignant pleural mesothelioma: preclinical rationale and clinical trials |
| Q33373158 | Hyperthermia combined with intra-thoracic chemotherapy and radiotherapy for malignant pleural mesothelioma |
| Q33339253 | Hyperthermic pleural perfusion with cisplatin: early clinical experience |
| Q37307952 | Identification of a seven glycopeptide signature for malignant pleural mesothelioma in human serum by selected reaction monitoring |
| Q36307991 | Imaging characteristics of pleural tumours |
| Q39728506 | Impact of Age on Long-Term Outcomes of Surgery for Malignant Pleural Mesothelioma |
| Q53341193 | Important prognostic factors in patients with malignant pleural mesothelioma, managed surgically. |
| Q39350596 | Induction chemotherapy vs post-operative adjuvant therapy for malignant pleural mesothelioma |
| Q33400437 | Induction chemotherapy, extrapleural pneumonectomy, and adjuvant radiotherapy for malignant pleural mesothelioma: experience of Guy's and St Thomas' hospitals |
| Q34616107 | Induction chemotherapy, extrapleural pneumonectomy, and postoperative high-dose radiotherapy for locally advanced malignant pleural mesothelioma: a phase II trial. |
| Q28206578 | Inhibitor of apoptosis protein-1 promotes tumor cell survival in mesothelioma |
| Q35960207 | Innovative therapies: intraoperative intracavitary chemotherapy |
| Q38809684 | Intensity-Modulated Radiation Therapy Improves the Target Coverage Over 3-D Planning While Meeting Lung Tolerance Doses for All Patients With Malignant Pleural Mesothelioma |
| Q51687498 | Intensity-modulated radiation therapy: a novel approach to the management of malignant pleural mesothelioma. |
| Q53102594 | Intensity-modulated radiotherapy and volumetric-modulated arc therapy for malignant pleural mesothelioma after extrapleural pleuropneumonectomy. |
| Q51687514 | Intensity-modulated radiotherapy following extrapleural pneumonectomy for the treatment of malignant mesothelioma: clinical implementation. |
| Q53586030 | Interim results of pleurectomy/decortication and intraoperative intrapleural hyperthermic cisplatin perfusion for patients with malignant pleural mesothelioma intolerable to extrapleural pneumonectomy. |
| Q39438165 | Intraoperative adjuncts for malignant pleural mesothelioma |
| Q39438162 | Intraoperative near-infrared imaging of mesothelioma |
| Q40324367 | Intrapleural hypotonic cisplatin treatment for malignant pleural mesothelioma: in vitro experiments and clinical application |
| Q34293068 | Investigational approaches for mesothelioma |
| Q44173242 | Kinetics of soluble mesothelin in patients with malignant pleural mesothelioma during treatment. |
| Q38255347 | Local and systemic therapies for malignant pleural mesothelioma |
| Q37340522 | Long-term results of intrathoracic chemohyperthermia (ITCH) for the treatment of pleural malignancies. |
| Q35208744 | Lung cancer * 8: Management of malignant mesothelioma |
| Q34616102 | Macroscopic complete resection: the goal of primary surgery in multimodality therapy for pleural mesothelioma. |
| Q37613240 | Making the case for molecular staging of malignant pleural mesothelioma |
| Q82051649 | Malignant Pleural Mesothelioma: A Population-Based Study of Survival |
| Q37209613 | Malignant mesothelioma: current status and perspective in Japan and the world |
| Q35020407 | Malignant mesothelioma: options for management |
| Q33954830 | Malignant pleural disease |
| Q83412919 | Malignant pleural mesothelioma |
| Q84107270 | Malignant pleural mesothelioma |
| Q79332820 | Malignant pleural mesothelioma in a 14-year-old boy with right aortic arch |
| Q35740408 | Malignant pleural mesothelioma--an update |
| Q55172221 | Malignant pleural mesothelioma-the impact of globalization on rare diseases. |
| Q40041012 | Malignant pleural mesothelioma: A retrospective analysis of clinicopathological and survival data. |
| Q36639812 | Malignant pleural mesothelioma: a comprehensive review |
| Q98467071 | Malignant pleural mesothelioma: between pragmatism and hope |
| Q30429528 | Malignant pleural mesothelioma: comparison of radical pleurectomy und extrapleural pneumonectomy |
| Q36834027 | Malignant pleural mesothelioma: current concepts in treatment |
| Q55113818 | Malignant pleural mesothelioma: diagnostic value of medical thoracoscopy and long-term prognostic analysis. |
| Q26821919 | Malignant pleural mesothelioma: incidence, etiology, diagnosis, treatment, and occupational health |
| Q38443843 | Malignant pleural mesothelioma: multidisciplinary experience in a public tertiary hospital |
| Q36728254 | Malignant pleural mesothelioma: update on treatment options with a focus on novel therapies. |
| Q37866786 | Malignant pleural mesothelioma: when is radiation therapy indicated? |
| Q38215513 | Management of malignant pleural mesothelioma-The European experience |
| Q36830116 | Management options for malignant pleural mesothelioma: clinical and cost considerations |
| Q38308730 | Matrix metalloproteinases 2 and 9 (gelatinases A and B) expression in malignant mesothelioma and benign pleura |
| Q37201356 | Mesothelioma and asbestos-related pleural diseases |
| Q35839385 | Mesothelioma: a review |
| Q81299291 | Mesothelioma: time to take stock |
| Q35535634 | Metabolic significance of the pattern, intensity and kinetics of 18F-FDG uptake in malignant pleural mesothelioma. |
| Q29248127 | Modern management of malignant pleural mesothelioma |
| Q39682388 | Molecular imaging of mesothelioma by detection of manganese-superoxide dismutase activity using manganese-enhanced magnetic resonance imaging |
| Q38012566 | Molecular pathogenesis of malignant mesothelioma |
| Q36822118 | Multicenter phase II trial of neoadjuvant pemetrexed plus cisplatin followed by extrapleural pneumonectomy and radiation for malignant pleural mesothelioma |
| Q43466291 | Multicentric study on malignant pleural mesothelioma in Turkey: clinicopathologic and survival characteristics of 282 patients. |
| Q24803699 | Multimodal treatment for resectable epithelial type malignant pleural mesothelioma |
| Q53181008 | Multimodality treatment of malignant pleural mesothelioma with or without immunotherapy: does it change anything? |
| Q40354488 | Neoadjuvant chemotherapy and extrapleural pneumonectomy of malignant pleural mesothelioma with or without hemithoracic radiotherapy (SAKK 17/04): a randomised, international, multicentre phase 2 trial |
| Q26859274 | New insights into understanding the mechanisms, pathogenesis, and management of malignant mesotheliomas |
| Q36157300 | New therapeutic options for mesothelioma |
| Q34998586 | Newly established ELISA for N-ERC/mesothelin improves diagnostic accuracy in patients with suspected pleural mesothelioma |
| Q50048236 | Outcomes of the Multimodal Treatment of Malignant Pleural Mesiothelioma: The Role of Surgery |
| Q82257520 | PET-guided dose escalation tomotherapy in malignant pleural mesothelioma |
| Q36828498 | Pathogenesis of malignant pleural mesothelioma and the role of environmental and genetic factors |
| Q81958277 | Pathogenesis of malignant pleural mesothelioma and the role of environmental and genetic factors |
| Q41697761 | Patterns of failure, toxicity, and survival after extrapleural pneumonectomy and hemithoracic intensity-modulated radiation therapy for malignant pleural mesothelioma |
| Q36295049 | Pegylated liposomal doxorubicin in malignant pleural mesothelioma: a possible guardian for long-term survival |
| Q33379936 | Pemetrexed plus carboplatin in elderly patients with malignant pleural mesothelioma: combined analysis of two phase II trials. |
| Q36118385 | Pemetrexed-cisplatin combination in mesothelioma |
| Q34678665 | Pericardial mesothelioma |
| Q36790055 | Perspective on malignant pleural mesothelioma diagnosis and treatment |
| Q74222595 | Phase II study of intravenous Doxil in malignant pleural mesothelioma |
| Q43634484 | Phase II trial of liposomal daunorubicin in malignant pleural mesothelioma |
| Q44874991 | Pleural mesothelioma: experience with 62 cases in 9 years |
| Q35903121 | Pleural mesothelioma: little evidence, still time to do trials |
| Q35960190 | Pleurectomy and decortication for malignant mesothelioma |
| Q55022610 | Pleurectomy/decortication versus extrapleural pneumonectomy: a critical choice. |
| Q37089137 | Pneumonectomy after chemoradiation: the Dana-Farber Cancer Institute/Brigham and Women's Hospital experience |
| Q35184119 | Positron emission tomography defines metastatic disease but not locoregional disease in patients with malignant pleural mesothelioma |
| Q37975136 | Practical approaches to diagnose and treat for T0 malignant pleural mesothelioma: a proposal for diagnostic total parietal pleurectomy |
| Q50049398 | Predictors of trimodality therapy and trends in therapy for malignant pleural mesothelioma |
| Q38843698 | Present and future roles of FDG-PET/CT imaging in the management of malignant pleural mesothelioma |
| Q40571570 | Prognosis of Fibrosarcoma in Patients With and Without a History of Radiation for Nasopharyngeal Carcinoma |
| Q42922993 | Prognostic Factors for Survival after Surgical Palliation of Malignant Pleural Effusion |
| Q24679305 | Prognostic factors for malignant mesothelioma in 142 patients: validation of CALGB and EORTC prognostic scoring systems |
| Q33918135 | Prognostic factors in elderly patients with malignant pleural mesothelioma: results of a multicenter survey |
| Q41981091 | Prognostic significance of cyclooxygenase-2 (COX-2) and expression of cell cycle inhibitors p21 and p27 in human pleural malignant mesothelioma |
| Q45970548 | Prognostic significance of metabolic response by positron emission tomography after neoadjuvant chemotherapy for resectable malignant pleural mesothelioma. |
| Q33390251 | Prognostic significance of p16/cdkn2a loss in pleural malignant mesotheliomas |
| Q37426353 | Prognostic value of 18F-FDG PET/CT in patients with malignant pleural mesothelioma |
| Q64234040 | Prolonged post-recurrence survival following pleurectomy/decortication for malignant pleural mesothelioma |
| Q53179959 | Proposed adjustments to pathologic staging of epithelial malignant pleural mesothelioma based on analysis of 354 cases. |
| Q37020881 | Protein kinase C beta in malignant pleural mesothelioma |
| Q55037897 | Proton beam therapy for malignant pleural mesothelioma. |
| Q55318621 | Quantitative Clinical Staging for Patients With Malignant Pleural Mesothelioma. |
| Q45020726 | Quantitative analyses at baseline and interim PET evaluation for response assessment and outcome definition in patients with malignant pleural mesothelioma. |
| Q47197708 | Radical multimodality therapy for malignant pleural mesothelioma. |
| Q44731776 | Radical surgery for mesothelioma: how can we obtain evidence? |
| Q24245556 | Radiotherapy for malignant pleural mesothelioma |
| Q37945636 | Raltitrexed in mesothelioma |
| Q79864094 | Recommendations for the reporting of pleural mesothelioma |
| Q50624261 | Reproducibility of histological subtyping of malignant pleural mesothelioma. |
| Q36822893 | Review of pemetrexed in combination with cisplatin for the treatment of malignant pleural mesothelioma |
| Q50050392 | Role of new radiation techniques in the treatment of pleural mesothelioma |
| Q51541835 | SEOM guidelines for the treatment of malignant pleural mesothelioma. |
| Q34129416 | Secretion of intelectin-1 from malignant pleural mesothelioma into pleural effusion |
| Q54678404 | Serum biomarkers in patients with mesothelioma and pleural plaques and healthy subjects exposed to naturally occurring asbestos. |
| Q43747147 | Significant augmentation of pro-apoptotic gene therapy by pharmacologic bcl-xl down-regulation in mesothelioma |
| Q45740888 | Simian virus-40 sequences are a negative prognostic cofactor in patients with malignant pleural mesothelioma |
| Q37862752 | Soluble markers for diagnosis of malignant pleural mesothelioma |
| Q34096881 | Soluble mesothelin related peptides (SMRP) and osteopontin as protein biomarkers for malignant mesothelioma: analytical validation of ELISA based assays and characterization at mRNA and protein levels |
| Q80100664 | Soluble mesothelin related protein in mesothelioma |
| Q54991391 | Staging in the era of international databases: documented improvements with remaining challenges. |
| Q30478608 | Statement on malignant mesothelioma in the United Kingdom |
| Q37867989 | Summary of prognostic factors and patient selection for extrapleural pneumonectomy in the treatment of malignant pleural mesothelioma |
| Q37762833 | Surgery for malignant pleural mesothelioma |
| Q38195607 | Surgical management of malignant pleural mesothelioma: impact of surgery on survival and quality of life-relation to chemotherapy, radiotherapy, and alternative therapies. |
| Q51716124 | Surgical resection of mesothelioma: an evidence-free practice. |
| Q30401535 | Surgical treatment of malignant pleural mesothelioma |
| Q34464373 | Survival after conservative (palliative) management of pleural malignant mesothelioma |
| Q53184110 | Survival and relapse pattern after trimodality therapy for malignant pleural mesothelioma. |
| Q38131498 | Systematic review of trimodality therapy for patients with malignant pleural mesothelioma |
| Q59137559 | The eighth TNM classification for malignant pleural mesothelioma |
| Q35232383 | The immunohistochemical characterization of sarcomatoid malignant mesothelioma of the pleura |
| Q52878999 | The management of the diaphragm during radical surgery for malignant pleural mesothelioma. |
| Q42995477 | The need for randomized trials in mesothelioma: let's walk the talk |
| Q38599311 | The role of radical radiotherapy in the management of malignant pleural mesothelioma: A systematic review |
| Q47809790 | The value of chest computer tomography and cervical mediastinoscopy in the preoperative assessment of patients with malignant pleural mesothelioma |
| Q53320850 | Therapeutic outcome according to histologic subtype in 121 patients with malignant pleural mesothelioma. |
| Q37044818 | Three-dimensional stereoscopic volume rendering of malignant pleural mesothelioma |
| Q44681845 | Treatment and survival analyses of malignant mesothelioma in Japan |
| Q40341641 | Treatment failure after extrapleural pneumonectomy for malignant pleural mesothelioma. |
| Q50050076 | Treatment for recurrence after extrapleural pneumonectomy for malignant pleural mesothelioma: A single institution experience |
| Q73400090 | Treatment of intervention sites of malignant pleural mesothelioma with radiotherapy: a Dutch-Belgian survey |
| Q79267484 | Tumor Necrosis Correlates With Angiogenesis and Is a Predictor of Poor Prognosis in Malignant Mesothelioma * |
| Q35880415 | Tumoral CD10 expression correlates with aggressive histology and prognosis in patients with malignant pleural mesothelioma. |
| Q47971165 | Using Gene Expression Ratios to Predict Outcome Among Patients With Mesothelioma |
| Q36887990 | Validation of a gene expression test for mesothelioma prognosis in formalin-fixed paraffin-embedded tissues |
| Q34715788 | Validation of genomics-based prognostic tests in malignant pleural mesothelioma |
| Q39211278 | Video-assisted cervical thoracoscopy: a novel approach for diagnosis, staging and pleurodesis of malignant pleural mesothelioma |
| Q87357879 | WITHDRAWN: Is there life after the Mesothelioma and Radical Surgery trial? Does extrapleural pneumonectomy still have a role in the management of pleural mesothelioma? A 13-year, single-center experience |
| Q37128016 | Which type of surgery should become the preferred procedure for malignant pleural mesothelioma: extrapleural pneumonectomy or extended pleurectomy? |
| Q83277189 | ["Therapeutic" pleural surgery] |
| Q55464730 | [Clinical analysis of 45 patients with malignant pleural mesothelioma]. |
| Q84192226 | [Cytoreductive surgery and hyperthermic intrathoracic chemotherapy perfusion] |
| Q80197048 | [Diagnosis and treatment of pleural effusion] |
| Q86613725 | [Intraoperative chemotherapy after radical pleurectomy or extrapleural pneumonectomy] |
| Q80426618 | [Malignant pleural mesothelioma: interrogations and hopes concerning the expected epidemic] |
| Q80352857 | [Malignant pleural mesothelioma: radiotherapy for the prevention of seeding nodules] |
| Q86911325 | [Regional treatment of malignant pleural mesothelioma: results from the tumor centre Regensburg] |
| Q81415520 | [Role of DNA microarrays in the diagnosis of pleural exudates: a feasibility study] |
| Q80064313 | [Surgery for malignant pleural mesothelioma] |
| Q38451233 | c-Kit is not expressed in malignant mesothelioma |
Search more.